WO2005030975A1 - α-グリコシルイソクエルシトリン、並びにその製造中間体及び副生成物の調製方法 - Google Patents
α-グリコシルイソクエルシトリン、並びにその製造中間体及び副生成物の調製方法 Download PDFInfo
- Publication number
- WO2005030975A1 WO2005030975A1 PCT/JP2004/013580 JP2004013580W WO2005030975A1 WO 2005030975 A1 WO2005030975 A1 WO 2005030975A1 JP 2004013580 W JP2004013580 W JP 2004013580W WO 2005030975 A1 WO2005030975 A1 WO 2005030975A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- wheat
- isoquercitrin
- gum
- rhamnose
- sodium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/40—Colouring or decolouring of foods
- A23L5/41—Retaining or modifying natural colour by use of additives, e.g. optical brighteners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
Definitions
- the present invention provides an antioxidant and anti-fading! !
- the present invention relates to a method of isoglyccitrin, which is a monoglycosyl isoquercitrin and its SSi intermediate, which are widely used in the field of food and cosmetics as a change inhibitor and the like.
- -Glycosyl isoquercitrin is a compound that has improved water solubility by glycosylating ⁇ of isoquercitrin, a poorly water-soluble flaponoid. Therefore, isoquercitrin can be used as an intermediate for producing CK-glycosylisoquercitrin.
- the present invention relates to a method for producing rhamnose, which is produced as a by-product in isoquercitrin i3 ⁇ 4i.
- Isoquercitrin also called isoquercetin
- isoquercetin is a compound that is found in plants such as dokudami, lahma (Yanglong tea), cucumber, ivy, shiromexa, and mulberry.
- antioxidant anti-fading, anti-scenting
- anti-UV anti-UV
- metal-chelating effects it is also known to have glandular, anti-inflammatory, capillary blood, and bimin effects. It is said to have a chemical effect such as a cosmetic effect, and is useful not only as an anti-fading agent for colored beverages and as an anti-change agent for foods, but also as a material for cosmetics and health products.
- Compound is a compound that is found in plants such as dokudami, lahma (Yanglong tea), cucumber, ivy, shiromexa, and mulberry.
- antioxidant antioxidant
- anti-UV anti-UV
- metal-chelating effects it is also known to have glandular, anti-inflammatory, capillar
- isoquercitrin In order for isoquercitrin to have an anti-fading effect and an antioxidant effect, it is necessary to have at least 0.001 w / V% or more of lit. It is difficult to apply to water-based products because it does not dissolve until water 0.01 wZv% @ ⁇ .
- Such ⁇ -glycosylisoquercitrin is prepared by a series of reactions, such as the above-mentioned glycosyltransferase treatment, through the production of isoquercitrin from rutin, and the reaction yield is further improved.
- Efficiency improvement is a matter that we need to consider now and improve. Examples of such a method include a method in which the reaction is observed under an Arita medium mixture (Japanese Patent Application Laid-Open No. 2002-52828), and a method in which the reaction is promoted using albumin or silk protein (Biocatalysis and Biotransformation, Vol. 14, pp. 113-123 (1996)) has been proposed. Disclosure of the invention
- An object of the present invention is to provide a method for producing ⁇ -daricosylisoquercitrin useful as an anti-oxidation thinner, anti-fading thinner, perfumed thinner, etc. with a high yield.
- the present invention provides a method for obtaining a high yield of iso-quercitrin, which is an intermediate of the glycosyl isoquercitrin, and a method for recovering rhamnose produced as a by-product with the production of iso-quercitrin.
- the aim is to provide a high rate iSt method.
- the present inventors have been discussing convertible fiber to solve the above-mentioned cafeteria, but when rutin is treated with naringinase, if it is given a specific edible ' It was found that isoquercitrin and rhamnose were obtained in yield. As mentioned above, isoquercitrin is the S3 ⁇ 4i intermediate of monoglycosyl isoquercitrin. Therefore, the present inventors have confirmed that ⁇ -glycosylisoc: peresitrine can be efficiently used by utilizing the above reaction.
- the present invention has been developed on the basis of a great deal of knowledge, and relates to a method for producing isoquercitrin, which is an intermediate for producing the following ⁇ -glycosylisoquercitrin:
- Fatty ester of glycerol consists of hexaglycerin distearate ester, tetraglycerin monooleate ester, tetraglycerin monostearate ester, decaglycerin monooleate ester, and decaglycerin stearate ester
- Item 3 A process of treating rutin with a naringin ⁇ tongue-enzyme under the cover of at least one edible pirates selected from food materials made from kudzu flour, potato starch, and so on. A process for obtaining isoquercitrin fractions from delicate products;
- Item 4 The food material made from wisteria is selected from the group consisting of rice, barley, wheat, rye, rye wheat, enpark, corn, barley, millet, corn, millet, pea, legumes, and wheat.
- Item 4. The method for producing isoquercitrin according to Item 3, which is a food material using the obtained syrup as a raw material.
- Item 5 An isoquere described in Item 3, wherein the food material made from fiber is a wheat-based food material selected from the group consisting of wheat protein, small fish, wheat bran, and a small piece of wheat. Citrine law.
- the present invention also relates to a $ 3 ⁇ 4t method of monoglycosyl soquercitrin, useful as a water-soluble flaponoid:
- Item 6 The following formula (1) comprising a step of treating isoquercitrin obtained by the Sii method according to any one of Items 1 to 5 with glycosyltransferase:
- Item 7 A method for producing glycosyl isoquercitrin according to Item 6, wherein ⁇ represented by the above formula (1) is S: of 1 to 7.
- the present invention relates to the r3 ⁇ 4nose S3 ⁇ 4 ⁇ method, which is by-produced during i3 ⁇ 4t of isoquercitrin: Item 8.
- Rutin is converted into gelatin, wheat dartene, chitosan, lecithin, glycerol oil, xanthan gum, carrageenan, chondroitin Sodium, casein, enzyme gelatin, sodium alginate, konjac extract, gellan gum, guar gum, soy protein, agar, pectin, yeast extract, egg white peptide, cluster dextrin, arabic gum, arginine, sodium metaphosphate At least one member selected from the group consisting of food ingredients, karaya gum, locust bean gum, sodium pyro pyro, dalcosamine, chitin, sodium glutamate, dextrin, and trehalose.
- the bottom of the food IW fraction treating with an enzyme that the Naringi down branch library ⁇ , and those, a step of get the rhamnose fraction from the physical object, rhamnose S ⁇ law.
- Item 9 The group consisting of glycerol lipoester consisting of hexaglycerin distearate ester, tetraglycerin monooleate ester, tetraglycerin monostearate ester, decaglycerin monooleate ester, and decaglycerin stearate ester
- the Ramnos' ⁇ method described in Item 8 which is at least one selected from the group consisting of:
- Rutin is treated with at least one kind of edible S ⁇ component selected from food ingredients that use kuzu, flour, potato starch, and IT as IT ingredients, and an enzyme having naringin-degrading activity.
- a rhamnose method comprising a step of treating and a step of obtaining a rhamnose fraction from the substance.
- Item 1 The food material made from wisteria is selected from the group consisting of rice, barley, wheat, rye, rye wheat, oats, corn, barley, millet, corn, millet, barley, beans, and barley.
- the rhamnois fiber method described in Item 10 which is a food material made from the raw material.
- the rhamnose according to item 10 is a wheat-based food material selected from the group consisting of wheat protein, koken, wheat bran, and small rice bran. Production method.
- the present invention also relates to the following:
- Item 1 4. ⁇ -glycosylisoquercitrin obtained by the method described in the above prefix 6 or 7, and ⁇ -daricosylisoquercitrin fiber. As shown in the following formula, isoquercitrin (b), rhamnose (c) and ⁇ -glycosyl isoquercitrin (d), which are the present invention, all use rutin (a) as a starting material. It is a useful compound that can be obtained i3 ⁇ 4i by the reaction of ⁇ and is widely used in the fields of food and cosmetics, etc.
- reaction 1 of the above formula when rutin (a) is subjected to ⁇ an enzyme having naringin enzyme (hereinafter also referred to as "naringin enzyme"), rhamnose wisteria is detached from rutin, and isoque ⁇ I recitrin (b ) Is generated.
- naringin enzyme an enzyme having naringin enzyme
- the present invention provides a $ 3 ⁇ 4i ⁇ method of isoquercitrin which makes it difficult to perform naringin desorption treatment under a specific edible fraction in Reaction 1 described above.
- the term “naringin tongue” refers to an enzyme that has the activity of degrading ⁇ to isoquercitrin and rhamnose, regardless of its name. is there.
- Typical examples of the enzyme having such activity include naringinase.
- rhamnosidase a-L-rhamnosidase: EC. 3.2.1.40
- hesperidinase hesperidinase
- vectorinase a-L-rhamnosidase
- the above-mentioned naringin is known to have a tongue. All of these enzymes are commercially available enzymes.
- Naringinase can be obtained from Amano Enzym Co., Ltd. ([Japan], for example, trade name: Naringina-1ze "Amano") or Tada Corporation [Japan ].
- naringinase is spread by a microorganism (naringinase-producing bacterium) belonging to Aspergillus' Niga 1 genus Nisylium etc.). For this reason, the naringinase-producing bacterium may be inoculated on a medium supplemented with rutin and reacted by a fermentation method to produce isoquercitrin, or naringinase or naringinase ⁇ ffi may be produced. It may be immobilized, and this may be batchwise and turned into rutin to produce isoquercitrin.
- Specific edible ingredients used in the present invention include gelatin, wheat dalten, chitosan, xanthan gum, carrageenan, sodium chondroitin sulfate, enzyme-compatible gelatin, sodium alginate, konjac extract, dielan gum, guar gum, agar, Thickeners such as pectin, cluster dextrin, gum arabic, karaya gum, locust bean gum, glucosamine, chitin, and dextrin; lecithin, and fatty acid esters of glycerol (eg, hexaglycerin distearate, te) Milky caseins such as triglycerin monostearate, tetraglycerin monooleate, and decaglycerin monooleate, decadariserine stearate) Bean protein, animal and vegetable protein were One had been ⁇ beauty egg white base peptide; arginine and glutamic acid sodium ⁇ amino such beam; sodium metaphosphate
- gelatin e.g., hexaglycerin distearate, tetraglycerin monostearate, decaglycerin stearate, etc.
- glycerol ester e.g., hexaglycerin distearate, tetraglycerin monostearate, decaglycerin stearate, etc.
- xanthan gum e.g., hexaglycerin distearate, tetraglycerin monostearate, decaglycerin stearate, etc.
- Carrageenan sodium chondroitin sulfate, casein
- enzyme gelatin sodium alginate, konjac extract, dielan gum, guar gum, short protein, agar, and various food materials made from D ⁇ .
- gelatin glycerol fatty acid ester (for example, hexaglycerin distearate, tetraglycerin monostearate, decaglycerin stearate, etc.), xanthan gum, power laginan, chondroitin sulfate sodium, casein, enzyme gelatin , Sodium alginate, konjac extract, and other food materials.
- glycerol fatty acid ester for example, hexaglycerin distearate, tetraglycerin monostearate, decaglycerin stearate, etc.
- ⁇ in the present invention means a crane of rice (a rice report), a view of a succulent fiber, and a crane of wheat.
- the seeds of cereals include rice, wheat, wheat, durum wheat, barley (including naked barley), rye, rye, embark, corn, fin, and foam.
- Sorghum, cane, and wheat can be mentioned.
- the test of shuku bells, which are served in detail, is to mention soybeans, red beans, mung beans, pigtails, chickpeas, and beans such as lentils "S”.
- ingredients include various food ingredients such as rice protein, rice bran, rice wisteria, and rice flour as raw materials; wheat flour (strong flour, semi-strong flour, medium flour, flour), wheat Wheat, wheat protein (wheat darten, wheat glutenin, wheat glutelin), small 3 ⁇ 4E sprouts (including I ⁇ fat fl.), Wheat bran and various flour-based food materials such as flour; large ⁇ 3 ⁇ 4 flour Various food materials made from rye such as rye flour; Enpaku! ⁇ ⁇ 3 ⁇ 4 Various food materials made from enpac such as flour; corn flour, corn ' «, corn grits Corn, corn and other corn-based food materials; barley-based food materials; foam-based food materials; corn!
- vegetable proteins such as wheat proteins (wheat dartene, wheat glutenin, wheat glutelin) and short proteins; scythes (strong flour, semi-strong flour, medium flour) are preferred. , Flour) and more preferably wheat protein.
- the reaction condition of naringin is not limited as long as the naringin exhibits the naringin property in a mixed water system of phosphorus, naringin enzyme and the above edible component.
- the amount of raw material is the amount of enzyme used to produce mg equivalent to lmg rhamnose in 30 minutes in a naringin solution (pH 3.5) with a constant amount of 100 units 1 unit) of naringin;
- ⁇ elementary: ⁇ , 0.0 can be shelf from 1 to 5 parts by weight. It is preferably 0.02 to 3 times * g order, more preferably 0.05 to 2 times.
- the consumption of one serving of edible food varies depending on the type of edible food, and cannot be regulated.For example, for a single rutin, 0.001 to 20 doubles, preferably 0.00 2 to 10 parts by weight, more preferably 0.05 to 5 parts by weight be able to.
- the amount of rutin in the reaction system is not particularly limited, but is usually 0.1 to 20% by weight in 100% by weight of the reaction system in order to efficiently use isoquercitrin. , Preferably 0.1 to 15% by weight, more preferably 0.1 to 10% by weight.
- the reaction system and PH conditions vary depending on the type of naringin ⁇ element to be stored.
- Amano Kozim shares ⁇ 3 ⁇ 4S ⁇ ⁇ naringinase 'ama, or the equivalent naringin ⁇ ! ⁇ ⁇ is ⁇ 5 ° Desirably less than C.
- the pH is preferably 6 to 4.
- the reaction can be carried out while standing or while using a fiber or ⁇ .
- the air in the head space of the reaction system may be replaced with an inert gas such as nitrogen, or an antioxidant ih such as ascorbic acid may be added to the system. .
- the rhamnose residue is eliminated from rutin, and the desired isoquercitrin is ripped with rhamnose.
- isocrine lucitrine can be purified from the system.
- the method for isosquercitrin is not particularly limited and can be carried out by arbitrarily combining conventional methods. '' Specifically, various resin treatment methods (adsorption method, ionization method, gel filtration method, etc.), »Science method ⁇ » Science method, Inverse method, Ion exchange method, Zeta densong, etc., Electrodeposition The method, the solvent fractionation method and the charcoal can be exemplified.
- Isoquercitrin thus obtained is itself used in the field of foods and cosmetics as an antioxidant, anti-fading, anti-flavoring agent and the like. In addition, it is used as a raw material for daricosil isoquercitrin. (Starting with rutin! ⁇ Charge: fc is the i3 ⁇ 4t intermediate of ⁇ -glycosylisoquercitrin). In addition, it is used as an intermediate for the ⁇ ⁇ ⁇ ⁇ -glycosylisoquercitrin. ⁇ , I Soquercitrin ⁇ it may be a crudely purified whip (for example, the above-mentioned at product), or may be in the state of the above reaction mixture.
- isoquercitrin itself is oxidized.
- ⁇ or the carrier is not particularly limited as long as it does not hinder the effects of the present invention.
- sucrose, crucose, fructose, mal! ⁇ Is, trehalose, learning sugar, oligosaccharide , Sugars such as dextrin, dextran, cyclodextrin, «, ⁇ candy, and isomerization; alcohols such as ethanol, propylene glycol, and glycerin; sorbitol, mannitol, erythritol, lactitol, xylitol, maltitol, palatinose And sugar alcohols such as Nada products; solvents such as triacetin; polysaccharides such as gum arabic, carrageenan, xanthan gum, guar gum, dielan gum, and vectin; and j.
- the additives include auxiliaries such as chelating agents, fragrances, exudates, and!.
- ⁇ powder, water droplet, and weave! ], Etc .; can be prepared into any form, such as a wavy and concentrated solution, or a semi-solid paste.
- the isoquercitrin (b) obtained by the above method is treated with a glucose-immobilizing enzyme, so that one or more darcosyls are added to the glycosyl salt of the isoquercitrin (b).
- the group is bonded to a single glycosyl isoquel Citrine (c) is produced.
- the present invention relates to the ⁇ it ⁇ method of ⁇ -glycosylisoc: lucitrin, wherein the reaction 2 uses the isoquercitrin (b) produced by the above-mentioned reaction 1 as a raw material.
- the isoquercitrin (b) used as a starting material for the reaction 2 may be any one obtained by the method described in (I) above, and its purification is not particularly limited.
- the above reaction 1 force ⁇ For the age of continuous reaction, the reaction 1 is concluded; by controlling the mixture to be insulted to, for example, 40 ° C or less, the precipitated isoquercitrin is collected and shelved. Can be.
- the method for producing ⁇ -glycosylisoquercitrin (c) from isoquercitrin (b) is not particularly limited, and any of the « ⁇ 3 ⁇ 4 ⁇ ⁇ method or a method developed in the future can be used.
- glucose is transferred to isoquercitrin (b) by using glucose transferase such as dalcosidase or trans-darcosidase to transfer glucose more than equimolar or more (hereinafter referred to as glycosylation).
- the glucose source used in the glycosylation may be any one that can transfer one or more of the darcos bacteria to one molecule of isoquercitrin (b).
- glucose, maltose, amylose, Amyctic pectin, starch, starch liquefied product, starch dandelion, dextrin, cyclodextrin and the like can be used.
- the conversion of the glucose source is usually 1 to 20 parts by weight, preferably 0.5 to 15 parts by weight, more preferably 0.5 to 15 parts by weight, based on 1 part by weight of isoquercitrin (b) in the reaction system.
- the ratio of 1 to 10% by weight ⁇ can be mentioned.
- darkosidase examples include ⁇ -amylase ( ⁇ . 3.2.1.1), ⁇ —darkosidase ( ⁇ . 3.2.1.20), and 3-amylase (EC 3.2.2. 1.2), dalcoamylase (EC 3.2.3.1.3) and the like, and as transdarkosidase, for example, cyclodextrin glucanotransferase ( ⁇ . C. 2.4.1) 19) (hereinafter abbreviated as CGTase).
- CGTase cyclodextrin glucanotransferase
- CGTase is produced by bacteria such as Bacillus such as Bacillus 'circulans, Notils' Macerans, Bacillus stearothermophilus, Bacillus megaterium, Bacillus polymixa, and Klebsiella such as Klebsiella 'Nyumoniae'. It is known that any one can freely access this invention Wear.
- glucose ⁇ transferases are commercially available enzymes, and simply use such commercially available enzyme preparations (eg, Amino Enzym Co., Ltd., trade name: Contizym, Japan). You can also.
- the enzyme need not necessarily be purified. As long as the object of the present invention can be achieved, crude enzyme may be used. For example, the glucose strain!
- 3 ⁇ 4 ⁇ transferase-producing bacterium may be fibrillated in a medium supplemented with isoctyllucitrin (b), and the reaction may be carried out by generation to produce «-glycosylisoquercitrin;
- glucose glucose transferase or glucose 3 ⁇ 43 ⁇ 43 ⁇ 4transferase ⁇ is immobilized, and this is reacted with isoquercitrin (b) in a patch-like manner or in a continuous fashion to form a glycosylysitol: relecitrin; You may.
- the reaction condition of glucose-transferase may be any condition in which glucose-S-transferase acts in a mixed water system of isoquercitrin (b), glucose reductase, and the above-mentioned glucose source.
- the amount of glucose residue transferase used is 1 part by weight of isoquercitrin (b) and the glucose transferase is the age of CGTase [enzyme lt3 ⁇ 4 'is also about 100 units (from soluble starch to ⁇ -cyclo
- the amount of the enzyme that produces 1 mg of dextrin per minute is defined as one unit.)]
- Iigil can be selected from the range of 0 ⁇ 001 to 20 times. Preferably, it is carried out in a range of 0.005 to 10% by weight, and more preferably in a range of 0.01 to 5% by weight.
- the amount of izouquercitrin (b) in the reaction system is not particularly limited. However, for the purpose of efficiently performing glycosylation, the amount of dizoquercitrin (b) is usually 0 ::! ⁇ 30% by weight, preferably 0.5-20% by weight, more preferably :! It is desirable that the content be contained at a ratio of about 10% by weight.
- the reaction system varies depending on the type of the enzyme to be used, but a range of about 80 or less can be appropriately selected and used. Industrially advantageous within this range are about 20-80 ° C, preferably about 40-75. C.
- the pH condition is usually about pH 3 to 11 or less, preferably pH 4 to 8.
- the reaction can be carried out statically or while stirring or stirring.
- the head space of the reaction system may be replaced with an inert gas such as nitrogen, or an antioxidant such as ascorbic acid may be added to the reaction system.
- an inert gas such as nitrogen
- an antioxidant such as ascorbic acid may be added to the reaction system.
- the glucose transferase can be used by using dalcosidase or transdarkosidase alone, or can be used in combination (simultaneously or differently).
- the glucose group is bonded to the glucose of isoquercitrin, and the desired ⁇ -daricosyl isoquercitrin is produced.
- the number of glucose groups bonded to glucose residues of isoquercitrin (the number of ⁇ in the above formula (1)) is not particularly limited, but is usually 1 to 30, preferably:! To 12, more preferably 1 to 7.
- The! ⁇ Number ( ⁇ number) of such a glucose group can be arbitrarily adjusted.
- various amylases ⁇ -amylase,) 3-amylase, darcoamylase, K-darcosidase, maltase, etc.
- ⁇ -daricosylisoquelecitrin can be isolated and purified from the reaction system of 2 (formula (1)) or the reaction system of the above amylase treatment.
- a method for example, a method in which —glycosyl isoquercitrin is precipitated by controlling the reaction system to be acidic can be mentioned.
- the method of ⁇ -glycosylisoquercitrin is not particularly limited, and any combination of conventional methods can be used.
- various resin treatment methods such as the coating method, the ion exchange method, and the gel filtration method), and the awakening method (P filter i J »method, paradoxical method, ion-method method, zeichiyuden method, etc.) , Den ⁇ !
- Examples include prayer, salting out, acid precipitation, recrystallization, solvent fractionation and rm'tt ⁇ as3 ⁇ 4. It is a flaponol glycoside in which glucose is further bound in equimolar amounts or more to glucose residues of lucetin 3-0-monodalcoside) and is easily soluble in water.
- isoquercitrin to exert its excellent functions (for example, antioxidant action, anti-fading action, anti-scent action) in a ⁇ -based solvent.
- antioxidant action for example, antioxidant action, anti-fading action, anti-scent action
- anti-scent action for example, antioxidant action, anti-fading action, anti-scent action
- water-soluble antioxidant, anti-fading and anti-scent change agent it is used in the food and perfumery fields. Can be used.
- a-Glycosylisoquercitrin can be used as an antioxidant, an antioxidant, an antiperfume inhibitor, etc., in addition to the above-mentioned isolated or prepared _glycosylisoquercitrin, !, carrier or additive.
- the composition is prepared by blending components such as an agent and performing an optional formulation treatment.
- the carrier is not particularly limited as long as it does not interfere with the effects of the present invention.
- sucrose, glucose, 3 ⁇ 4, maltose, trehalose, ⁇ J oligosaccharide, dextrin, dextran ,
- alcohols such as ethanol, propylene glycol, and glycerin
- sugar alcohols such as sorbitol, mannitol, erythritol, lactitol, xylitol, maldetol, 3 ⁇ 4palatinose, and the like
- Solvents such as triacetin; polysaccharides such as gum arabic, carrageenan, xanthan gum, guar gum, dielan gum, and pectin; or the ability to name water? Wear.
- auxiliaries such as chelating agents, perfumes, can be ⁇ 1 include incense
- Such a woven ij is not particularly limited in its form, such as solid, such as ⁇ powder, granules, and cats; wavy, spilled liquid, or semi-solid paste. It can be prepared in any form.
- the present invention also provides a method for rhamnose characterized in that naringin-W elemental treatment is performed under specific edible ⁇ in the above.
- the i ⁇ ⁇ i of the rhamnose can be obtained from rutin (a) as a raw material according to the method of Reaction 1 described above in (I).
- naringin ⁇ W treatment yields a reaction mixture containing rhamnose (isoquercitrin, rhamnose, and unreacted rutin), but it is also possible to isolate and purify rhamnose from the mixture if necessary. In monkey.
- ⁇ sparingly soluble isoquercitrin is precipitated, and it is obtained by conventional solid dissociation such as centrifugation or filtration.
- Rhamnose can be recovered from the obtained liquid phase.
- the recovered rhamnose can be further subjected to clarification.
- the method for purifying rhamnose is not particularly limited, and conventional methods can be arbitrarily combined. Specifically, various resin treatment methods (adsorption method, ion exchange, gel filtration, etc.), thigh method, paradoxical method, ion method, zeta removal, etc., electrolysis (f method, solvent The fractionation method and 03 ⁇ 43 ⁇ 41 theory can be exemplified.
- the rhamnose thus obtained is used, for example, as a source, sweet, food m & n product, and pharmaceutical additive in the food field, pharmaceuticals, quasi-drugs, and cosmetics. Further, for example, it can be suitably used as a raw material for pharmaceuticals, cosmetics, and m-modified ssg as a request for difficulty in flavoring such as furaneol.
- isoquercitrin which is a 3 ⁇ 4 ⁇ intermediate of ⁇ -glycosyl isoquercitrin
- the present invention is useful not only as an efficient method for isoquercitrin, but also as an efficient method for producing Q! -Glycosylisoquery recitrin.
- isoquercitrin is produced from rutin
- rhamnose is produced. Therefore, from another viewpoint, the present invention relating to the rhamnose SSi method is useful as a method capable of producing rhamnose as a sugar source in a high yield from rutin at a high yield.
- Migrating eye Mixing 15 volume% acetonitrile and 0.085 wZv% phosphoric acid Mimetic: 0.8 mL / min
- Example 2 To 2 kg of isosquercitrin obtained in Example 1 above, 100 L of water was added, and 8 kg of corn starch was added to homogenize. Add 200ml of CGTas e (Amano Enzym Co., Ltd., trade name Conchizam, Japan), and add i60. C, and maintained at pH 7.25 for 26 hours. The obtained anti-night was passed through an adsorption resin column (Diaion HP-21, manufactured by Sansei Co., Ltd., Japan) to adsorb ⁇ -glycosylisoquercitrin and washed with water. The mixture was desorbed by passing through methanol water ⁇ After the desorbed solution was concentrated, solid was obtained.
- CGTas e Mano Enzym Co., Ltd., trade name Conchizam, Japan
- the obtained solids were subjected to high performance liquid chromatography (HPLC, manufactured by Nippon ⁇ 3 ⁇ 4 Co., Ltd., column ODS, elution night 25% by volume THFZ 0.01% phosphorous M / JO), and each peak fraction (each component) , And the obtained components were analyzed using a mass spectrometer (MS, manufactured by Nissu Seisakusho Co., Ltd., Model M-80B, Japan).
- MS mass spectrometer
- n 1 or more.
- Example 4 The remaining amount of isoquercitrin, which was obtained by filtering off isoquercitrin from the night of rutin, naringinase and edible components obtained in Example 1, was used as an adsorbent resin column (diamond manufactured by Sankei Densei Co., Ltd.). (Ion HP-21, Japan). Next, the fraction ⁇ ⁇ »is filtered through a nominal 10,000-liter filter, and the obtained fraction ⁇ ⁇ The fraction less than the nominal 10,000 is further treated with cations and anions. And eluate obtained? By ravenging rhamnose was collected.
- Example 4 The remaining amount of isoquercitrin, which was obtained by filtering off isoquercitrin from the night of rutin, naringinase and edible components obtained in Example 1, was used as an adsorbent resin column (diamond manufactured by Sankei Densei Co., Ltd.). (Ion HP-21, Japan). Next, the fraction
- the present invention is useful not only as an efficient am ⁇ method for isoquercitrin, but also as an efficient method for producing 0! -Glycosylleisoquercitrin. Further, the method of the present invention according to claims 6 and 7 is useful as an efficient S3 ⁇ 4t ⁇ method for ⁇ -glycosylisoquery recitrin.
- rhamnose is firstarily produced as isoquercitrin is produced from rutin. Therefore, from another viewpoint, the present invention provides the law of rhamnose (claims 8 to 12).
- the present invention is useful as a method for rhamnose, which is a sugar source, from SS in high yield from rutin.
- Isoquercitrin IJ and Hi-Glycosylisoquercitrin IJ described in claims 13 and 14 are useful in the field of food products, cosmetics, etc., in order to prevent oxidation _ ⁇ , anti-fading ih, and 03 ⁇ 4. »It is useful as a dangou it ⁇ .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE602004024097T DE602004024097D1 (de) | 2003-09-29 | 2004-09-10 | Verfahren zur herstellung von alpha-glycosylisoquercitrin, zugehörige zwischenstufe sowie nebenprodukt |
JP2005514173A JP4498277B2 (ja) | 2003-09-29 | 2004-09-10 | α−グリコシルイソクエルシトリン、並びにその製造中間体及び副生成物の調製方法 |
EP04773224A EP1669462B1 (en) | 2003-09-29 | 2004-09-10 | Method of preparing alpha-glycosylisoquercitrin, intermediate therefor and by-product |
AT04773224T ATE448317T1 (de) | 2003-09-29 | 2004-09-10 | Verfahren zur herstellung von alpha- glycosylisoquercitrin, zugehörige zwischenstufe sowie nebenprodukt |
KR1020067006169A KR101086441B1 (ko) | 2003-09-29 | 2004-09-10 | α-글리코실이소퀘르시트린, 그의 제조 중간체, 및부생성물의 조제 방법 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-338689 | 2003-09-29 | ||
JP2003338689 | 2003-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005030975A1 true WO2005030975A1 (ja) | 2005-04-07 |
Family
ID=34386169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/013580 WO2005030975A1 (ja) | 2003-09-29 | 2004-09-10 | α-グリコシルイソクエルシトリン、並びにその製造中間体及び副生成物の調製方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7691425B2 (ja) |
EP (1) | EP1669462B1 (ja) |
JP (1) | JP4498277B2 (ja) |
KR (1) | KR101086441B1 (ja) |
CN (1) | CN100413975C (ja) |
AT (1) | ATE448317T1 (ja) |
DE (1) | DE602004024097D1 (ja) |
WO (1) | WO2005030975A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008099683A (ja) * | 2006-09-22 | 2008-05-01 | Sanei Gen Ffi Inc | 高甘味度甘味料の呈味改善方法 |
JPWO2007125578A1 (ja) * | 2006-04-27 | 2009-09-10 | 株式会社ノエビア | 保湿剤、美白剤及び痩身剤 |
JP2013215155A (ja) * | 2012-04-11 | 2013-10-24 | Kao Corp | 難水溶性ポリフェノール類の糖付加物の製造方法 |
JP2014012027A (ja) * | 2006-09-22 | 2014-01-23 | Sanei Gen Ffi Inc | 高甘味度甘味料の呈味改善方法 |
JP2017105775A (ja) * | 2015-12-04 | 2017-06-15 | 三栄源エフ・エフ・アイ株式会社 | 経口組成物用添加剤 |
JP2017105774A (ja) * | 2015-12-04 | 2017-06-15 | 三栄源エフ・エフ・アイ株式会社 | 唾液分泌促進剤 |
WO2018190378A1 (ja) * | 2017-04-12 | 2018-10-18 | サントリーホールディングス株式会社 | ステビア由来ラムノース合成酵素及び遺伝子 |
JP6421280B1 (ja) * | 2017-07-28 | 2018-11-07 | 太陽化学株式会社 | フラボノイド包接化合物の製造方法 |
JP6616046B1 (ja) * | 2018-06-01 | 2019-12-04 | 太陽化学株式会社 | フラボノイド−シクロデキストリン包接化合物を含有する組成物 |
WO2020153406A1 (en) * | 2019-01-24 | 2020-07-30 | Alps Pharmaceutical Ind. Co., Ltd. | Isoquercitrin compositions |
US10918654B1 (en) | 2019-09-23 | 2021-02-16 | Alps Pharmaceutical Ind. Co., Ltd. | Rutin compositions |
US11110109B2 (en) | 2019-10-22 | 2021-09-07 | Alps Pharmaceutical Ind. Co., Ltd. | Water soluble O-glycosyl flavonoid compositions and methods for preparing same |
US11266671B2 (en) | 2018-04-23 | 2022-03-08 | Alps Pharmaceutical Ind. Co., Ltd. | Compositions of O-glycosyl flavonoids |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2347119B2 (es) * | 2009-04-22 | 2011-04-28 | Universidad De Santiago De Compostela | Nanocapsulas de poliarginina. |
EP3384786B1 (en) * | 2015-12-04 | 2022-03-09 | San-Ei Gen F.F.I., INC. | Use of enzyme-modified isoquercitrin |
CN107119086B (zh) * | 2017-05-27 | 2021-12-21 | 华南理工大学 | 一种基于黑曲霉细胞催化芦丁水解制备异槲皮苷的方法 |
CN109438536A (zh) * | 2018-10-29 | 2019-03-08 | 广东金骏康生物技术有限公司 | 一种异槲皮素及其衍生物的应用与制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01213293A (ja) * | 1988-02-22 | 1989-08-28 | San Ei Chem Ind Ltd | 水易溶性フラボノール配糖体の製法 |
JP2002528133A (ja) * | 1998-10-30 | 2002-09-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ルチノシドの酵素的分解方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8727223D0 (en) | 1987-11-20 | 1987-12-23 | Unilever Plc | Preparing l-rhamnose |
JP2898019B2 (ja) | 1989-08-21 | 1999-05-31 | 三栄源エフ・エフ・アイ株式会社 | 水難溶性フラボノイドの溶解方法 |
JP3510717B2 (ja) * | 1995-09-29 | 2004-03-29 | 三栄源エフ・エフ・アイ株式会社 | 活性酸素・フリーラジカル消去活性を有する飲食品 |
JP3155466B2 (ja) * | 1996-07-03 | 2001-04-09 | 東洋精糖株式会社 | 水溶性ケルセチン配糖体含有物およびその製造方法 |
EP1546356A2 (en) * | 2002-09-23 | 2005-06-29 | Her Majesty The Queen in Right of Canada, as represented by The Minister of Agriculture and Agri-Food | Extraction, purification and conversion of flavonoids from plant biomass |
-
2003
- 2003-12-22 US US10/740,607 patent/US7691425B2/en active Active
-
2004
- 2004-09-10 AT AT04773224T patent/ATE448317T1/de not_active IP Right Cessation
- 2004-09-10 DE DE602004024097T patent/DE602004024097D1/de active Active
- 2004-09-10 KR KR1020067006169A patent/KR101086441B1/ko active IP Right Grant
- 2004-09-10 JP JP2005514173A patent/JP4498277B2/ja active Active
- 2004-09-10 WO PCT/JP2004/013580 patent/WO2005030975A1/ja active Application Filing
- 2004-09-10 CN CNB2004800282801A patent/CN100413975C/zh active Active
- 2004-09-10 EP EP04773224A patent/EP1669462B1/en not_active Not-in-force
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01213293A (ja) * | 1988-02-22 | 1989-08-28 | San Ei Chem Ind Ltd | 水易溶性フラボノール配糖体の製法 |
JP2002528133A (ja) * | 1998-10-30 | 2002-09-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ルチノシドの酵素的分解方法 |
Non-Patent Citations (2)
Title |
---|
ELLENRIEDER G., DAZ M.: "Thermostabilizatoin of naringinase from penicillium decumbens by proteins in soluti on and immobilization on insoluble proteins", BIOCATALYSIS AND BIOTRANSFORMATION, vol. 14, no. 2, 1996, pages 113 - 123, XP002904143 * |
ONO M.: "Heat stability of naringinase", NIPPON NOGEI KAGAKU KAISHI, vol. 53, no. 7, 1979, pages 243 - 5, XP002904142 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2007125578A1 (ja) * | 2006-04-27 | 2009-09-10 | 株式会社ノエビア | 保湿剤、美白剤及び痩身剤 |
JP5294847B2 (ja) * | 2006-04-27 | 2013-09-18 | 株式会社ノエビア | 保湿剤、美白剤及び痩身剤 |
JP2008099683A (ja) * | 2006-09-22 | 2008-05-01 | Sanei Gen Ffi Inc | 高甘味度甘味料の呈味改善方法 |
JP2014012027A (ja) * | 2006-09-22 | 2014-01-23 | Sanei Gen Ffi Inc | 高甘味度甘味料の呈味改善方法 |
JP2013215155A (ja) * | 2012-04-11 | 2013-10-24 | Kao Corp | 難水溶性ポリフェノール類の糖付加物の製造方法 |
JP2017105775A (ja) * | 2015-12-04 | 2017-06-15 | 三栄源エフ・エフ・アイ株式会社 | 経口組成物用添加剤 |
JP2017105774A (ja) * | 2015-12-04 | 2017-06-15 | 三栄源エフ・エフ・アイ株式会社 | 唾液分泌促進剤 |
WO2018190378A1 (ja) * | 2017-04-12 | 2018-10-18 | サントリーホールディングス株式会社 | ステビア由来ラムノース合成酵素及び遺伝子 |
US11447765B2 (en) | 2017-04-12 | 2022-09-20 | Suntory Holdings Limited | Rhamnose synthase derived from stevia and gene |
JP7011649B2 (ja) | 2017-04-12 | 2022-02-10 | サントリーホールディングス株式会社 | ステビア由来ラムノース合成酵素及び遺伝子 |
JPWO2018190378A1 (ja) * | 2017-04-12 | 2020-02-20 | サントリーホールディングス株式会社 | ステビア由来ラムノース合成酵素及び遺伝子 |
CN110462052A (zh) * | 2017-07-28 | 2019-11-15 | 太阳化学株式会社 | 黄酮包合化合物的制造方法 |
WO2019021510A1 (ja) * | 2017-07-28 | 2019-01-31 | 太陽化学株式会社 | フラボノイド包接化合物の製造方法 |
US10519182B2 (en) | 2017-07-28 | 2019-12-31 | Taiyo Kagaku Co., Ltd. | Method for producing flavonoid inclusion compound |
JP2019024500A (ja) * | 2017-07-28 | 2019-02-21 | 太陽化学株式会社 | フラボノイド包接化合物の製造方法 |
US10676496B2 (en) | 2017-07-28 | 2020-06-09 | Taiyo Kagaku Co., Ltd. | Method for producing flavonoid inclusion compound |
JP2019134714A (ja) * | 2017-07-28 | 2019-08-15 | 太陽化学株式会社 | フラボノイド包接化合物の製造方法 |
JP6421280B1 (ja) * | 2017-07-28 | 2018-11-07 | 太陽化学株式会社 | フラボノイド包接化合物の製造方法 |
US11266671B2 (en) | 2018-04-23 | 2022-03-08 | Alps Pharmaceutical Ind. Co., Ltd. | Compositions of O-glycosyl flavonoids |
JP6616046B1 (ja) * | 2018-06-01 | 2019-12-04 | 太陽化学株式会社 | フラボノイド−シクロデキストリン包接化合物を含有する組成物 |
WO2019230013A1 (ja) * | 2018-06-01 | 2019-12-05 | 太陽化学株式会社 | フラボノイド-シクロデキストリン包接化合物を含有する組成物 |
CN112236525A (zh) * | 2018-06-01 | 2021-01-15 | 太阳化学株式会社 | 含有类黄酮-环糊精包合物的组合物 |
US11446319B2 (en) | 2018-06-01 | 2022-09-20 | Taiyo Kagaku Co., Ltd. | Composition containing flavonoid-cyclodextrin clathrate compound |
WO2020153406A1 (en) * | 2019-01-24 | 2020-07-30 | Alps Pharmaceutical Ind. Co., Ltd. | Isoquercitrin compositions |
JP2020117478A (ja) * | 2019-01-24 | 2020-08-06 | アルプス薬品工業株式会社 | イソクエルシトリン組成物 |
US10918654B1 (en) | 2019-09-23 | 2021-02-16 | Alps Pharmaceutical Ind. Co., Ltd. | Rutin compositions |
US11110109B2 (en) | 2019-10-22 | 2021-09-07 | Alps Pharmaceutical Ind. Co., Ltd. | Water soluble O-glycosyl flavonoid compositions and methods for preparing same |
Also Published As
Publication number | Publication date |
---|---|
EP1669462A4 (en) | 2008-10-08 |
EP1669462B1 (en) | 2009-11-11 |
EP1669462A1 (en) | 2006-06-14 |
KR101086441B1 (ko) | 2011-11-25 |
CN1860239A (zh) | 2006-11-08 |
DE602004024097D1 (de) | 2009-12-24 |
JPWO2005030975A1 (ja) | 2006-12-07 |
ATE448317T1 (de) | 2009-11-15 |
US20080187622A1 (en) | 2008-08-07 |
JP4498277B2 (ja) | 2010-07-07 |
KR20060096425A (ko) | 2006-09-11 |
CN100413975C (zh) | 2008-08-27 |
US7691425B2 (en) | 2010-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005030975A1 (ja) | α-グリコシルイソクエルシトリン、並びにその製造中間体及び副生成物の調製方法 | |
JP3896577B2 (ja) | クエルセチン配糖体組成物およびその調製方法 | |
JP2022082472A (ja) | 高純度ステビオールグリコシド | |
EP3464607B1 (en) | Glycosylated steviol glycoside compositions | |
CN110191643B (zh) | 甜菊醇糖苷的生物合成生产及其工艺 | |
JP4983258B2 (ja) | イソサイクロマルトオリゴ糖及びイソサイクロマルトオリゴ糖生成酵素とそれらの製造方法並びに用途 | |
KR19980042215A (ko) | 코지비오스 포스포릴라아제, 그 제조방법 및 용도 | |
KR101129098B1 (ko) | 환상 말토실 말토오스 및 환상 말토실 말토오스 생성효소와이들의 제조 방법 및 용도 | |
JP7449526B2 (ja) | エクオール誘導体の産生のための組成物 | |
JP2003160595A (ja) | 糖誘導体 | |
KR100877278B1 (ko) | α-이소말토실 전이효소 활성을 가진 폴리펩티드 | |
Klingel et al. | Enzymatic synthesis and characterization of mono-, oligo-, and polyglucosylated conjugates of caffeic acid and gallic acid | |
JP2009521240A (ja) | プレバイオティックオリゴ糖6−ケストースを得るための新規フルクトフラノシダーゼ活性 | |
KR100647404B1 (ko) | 트레할로오스 포스포릴라아제, 그 제조방법 및 용도 | |
EP4257183A1 (en) | Prebiotic composition for butyric acid bacteria | |
JP5943587B2 (ja) | ジンゲロール配糖体、その製造方法およびその用途 | |
JP7441178B2 (ja) | シクロイソマルトテトラオース、シクロイソマルトテトラオース生成酵素とそれらの製造方法並びに用途 | |
WO2022186355A1 (ja) | 6,3'-ジヒドロキシエクオールの産生のための組成物 | |
WO2012161250A1 (ja) | α-グルコシダーゼ、その製造方法およびその用途、並びにジンゲロール配糖体、その製造方法およびその用途 | |
AU2718499A (en) | Process for the preparation of sotolon | |
JP2005210925A (ja) | グルコシル基の転移方法 | |
JP2008247768A (ja) | 活性酸素消去剤とその利用法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480028280.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005514173 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004773224 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067006169 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004773224 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067006169 Country of ref document: KR |